Surgery
Volume 146, Issue 6 , Pages 971-978 , December 2009

Personalized medicine: The future is not what it used to be

  • Michael J. Demeure, MD, MBA

      Affiliations

    • Corresponding Author InformationReprint requests: Michael J. Demeure, MD, MBA, Virginia G. Piper Cancer Center, 10460 N 92nd Street, Suite 200, Scottsdale, AZ 85258.

,Accepted 5 October 2009.

References 

  1. You YN, Lakhani VT, Wells SA. The role of prophylactic surgery in cancer prevention. World J Surg. 2007;31:450–464
  2. Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomäki P, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829–834
  3. Syngal S, Weeks JC, Schrag D, Garber JE, Kuntz KM. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med. 1998;129:787–796
  4. Olschwang P, Laurent-Puig , Eisinger F, Millat B. An alternative to prophylactic colectomy for colon cancer prevention in HNPCC syndrome. Gut. 2005;54:169
  5. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62:676–689
  6. King MC, Marks JH, Mandell JB. New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643–646
  7. Brekelmans CTM, Seynaeve C, Bartels CC, Tilanus-Linthorst MM, Meijers-Heijboer EJ, Crepin CM, et al. Rotterdam Committee for Medical and Genetic Counseling. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol. 2001;19:924–930
  8. King M, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. National Surgical Adjuvant Breast and Bowel Project. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286:2251–2256
  9. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:159–164
  10. Hartman LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Nat Cancer Inst. 2001;93:1633–1637
  11. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces the breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22:1055–1062
  12. Frost MH, Schaid DJ, Sellers TA, Slezak JM, Arnold PG, Woods JE, et al. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA. 2000;284:319–324
  13. Heshmati HM, Gharib H, van Heerden JA, Sizemore GW. Advances and controversies in the diagnosis and management of medullary thyroid cancer. Am J Med. 1997;103:60–69
  14. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, et al. Mutations in the RET proto-oncogene are associated with MEN2A and FMTC. Hum Mol Genet. 1993;2:851–856
  15. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363:458–460
  16. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276:1575–1579
  17. Wells SA, Chi DD, Toshima K, Dehner LP, Coffin CM, Dowton SB, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia 2A. Ann Surg. 1994;220:237–247
  18. Quayle FJ, Fialkowski EA, Benveniste R, Moley JF. Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery. 2007;142:800–805
  19. Machens A, Braukhoff M, Holzhausen H-J, Thanh PN, Lehnert H, Dralle H. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2005;90:3999–4003
  20. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, et al. Neuronal apoptosis linked to EgIN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell. 2005;8:155–167
  21. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12:245–262
  22. Ries LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2004. Bethesda, MD: National Cancer Institute; 2007;Available from: URL: http//seer.cancer.gov/csr/1975_2004
  23. Xing M. BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocrine Rev. 2007;28:742–762
  24. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta. 2003;1653:25–40
  25. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer. 2007;110:38–46
  26. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, et al. Association of BRAF V600E mutation with poor clinicopathologic outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:4085–4090
  27. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90:6373–6379
  28. Magnaldo T. SHH (Sonic hedgehog). Atlas Genet Cytogenet Oncol Haematol. February 2002. Available from: URL: http://AtlasGeneticsOncology.org/Genes/SHHID378.html.
  29. Hambley TW, Hait WN. Is anticancer drug development heading in the right direction?. Cancer Res. 2009;69:1259–1261
  30. Check Hayden E. Cancer complexity slows quest for cure. Nature. 2008;455:148

PII: S0039-6060(09)00633-3

doi: 10.1016/j.surg.2009.10.023

Surgery
Volume 146, Issue 6 , Pages 971-978 , December 2009

Article Tools